NYSE$ATR
AptarGroup Inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
AptarGroup's third quarter results were released, showcasing sales growth driven by Beauty + Home and Food + Beverage segments, while Pharma segment experienced a slight sales decline.
AptarGroup reported a 9% increase in sales, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage. Pharma sales declined slightly. Earnings per share were $0.70, and adjusted earnings per share were $0.94. The company completed acquisitions of Weihai Hengyu Medical Products and a majority stake in Voluntis.
- Reported sales grew 9%, driven by double-digit core sales growth in Beauty + Home and Food + Beverage.
- Core sales (excluding currency effects) increased 8%.
- Pharma sales declined slightly compared to the prior year.
- Adjusted earnings per share totaled $0.94, excluding certain charges.
Headline financials
Revenue & EPS history
AptarGroup · Revenue · Quarterly
$825M
Revenue by segment
AptarGroup · $825M total across 3 segments · Q3 2021
- Beauty$374M+10.9%45.3%
- Pharma$313M-0.8%37.9%
- Closures$138M+30.1%16.7%
Forward guidance
Aptar expects core sales growth in each business segment for the fourth quarter of 2021. Earnings growth is expected to be tempered due to the business mix in the Pharma segment, sequential foreign currency translation headwinds, rising inflation, and supply chain disruptions.
Tailwinds
- Core sales growth is expected in each business segment.
- Further, gradual progress in the beauty market is anticipated.
- Continued good sales momentum is expected in elastomer components.
- Continued good sales momentum is expected in active material solutions.
- Focus on cost containment and increasing prices to offset rising input costs.
Headwinds
- Earnings growth is expected to be tempered due to the business mix in the Pharma segment.
- Sequential foreign currency translation headwinds.
- Rising inflation.
- Supply chain disruptions including labor shortages.
- Difficult comparisons for prescription drug delivery devices and food and beverage closures markets.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.3%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+1.2%
Avg return
30 days after
63%
43 / 68 earnings
Positive
+9.2%
Q4 2017
Best reaction
-9.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.3% | -0.8% | -6.4% | |
| Q4 2025 | +8.3% | +12.9% | +6.5% | |
| Q3 2025 | -9.0% | -7.1% | +0.3% | |
| Q1 2025 | +2.3% | +2.1% | +6.8% | |
| Q4 2024 | -8.5% | -9.4% | -2.3% | |
| Q3 2024 | +0.8% | +0.6% | +2.3% | |
| Q2 2024 | +1.7% | +1.1% | +4.4% | |
| Q1 2024 | +2.4% | +3.1% | +5.8% | |
| Q4 2023 | +5.4% | +3.1% | +8.6% | |
| Q3 2023 | +0.1% | -0.9% | +4.2% | |
| Q2 2023 | +3.2% | +2.1% | +6.3% | |
| Q1 2023 | +2.4% | +4.1% | -1.4% | |
| Q4 2022 | +5.7% | +4.2% | +0.3% | |
| Q3 2022 | +2.1% | -1.9% | +6.9% | |
| Q2 2022 | +1.6% | +0.5% | -1.5% | |
| Q1 2022 | +3.4% | +2.5% | -2.0% | |
| Q4 2021 | +3.3% | +3.8% | +2.7% | |
| Q3 2021 | -3.6% | +1.7% | +1.0% | |
| Q2 2021 | -6.3% | -6.6% | -2.3% | |
| Q1 2021 | -0.2% | +2.6% | -2.5% | |
| Q4 2020 | -7.7% | -10.4% | -2.7% | |
| Q3 2020 | +1.6% | +6.4% | +13.3% | |
| Q2 2020 | -3.0% | -0.2% | -0.6% | |
| Q1 2020 | -3.6% | -4.1% | +1.2% | |
| Q4 2019 | -2.6% | -7.0% | -19.6% | |
| Q3 2019 | -7.1% | -8.9% | -6.0% | |
| Q2 2019 | -5.0% | -5.4% | -1.3% | |
| Q1 2019 | +1.3% | +2.3% | +2.0% | |
| Q4 2018 | +1.5% | +0.0% | +2.2% | |
| Q3 2018 | +1.8% | +2.1% | +2.0% | |
| Q2 2018 | +8.6% | +8.1% | +9.6% | |
| Q1 2018 | +0.3% | +0.4% | +1.0% | |
| Q4 2017 | +9.2% | +11.8% | +9.6% | |
| Q3 2017 | -0.6% | -1.6% | -2.5% | |
| Q2 2017 | -6.5% | -6.3% | -6.4% | |
| Q1 2017 | +1.2% | +1.1% | +6.3% | |
| Q4 2016 | +1.7% | +0.4% | +4.4% | |
| Q3 2016 | -4.3% | -7.4% | -0.3% | |
| Q2 2016 | -1.9% | -3.9% | -1.6% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | +8.3% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | +1.8% | — | — | |
| Q3 2014 | +2.0% | — | — | |
| Q2 2014 | -3.5% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q4 2013 | +1.9% | — | — | |
| Q3 2013 | +0.2% | — | — | |
| Q2 2013 | -2.1% | — | — | |
| Q1 2013 | -2.0% | — | — | |
| Q4 2012 | -0.8% | — | — | |
| Q3 2012 | -3.5% | — | — | |
| Q2 2012 | +2.6% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q3 2011 | +5.8% | — | — | |
| Q2 2011 | -5.0% | — | — | |
| Q1 2010 | +2.2% | — | — | |
| Q1 2011 | +2.3% | — | — | |
| Q4 2008 | +1.5% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q3 2010 | +2.9% | — | — | |
| Q3 2009 | +2.9% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q2 2009 | +0.5% | — | — | |
| Q2 2010 | +0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro